



(51) International Patent Classification:

A61P 3/04 (2006.01) A61K 31/4985 (2006.01)
C07K 16/28 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2022/075545

(22) International Filing Date:

26 August 2022 (26.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/238,068 27 August 2021 (27.08.2021) US
63/301,012 19 January 2022 (19.01.2022) US
63/333,351 21 April 2022 (21.04.2022) US

(71) Applicant: **VERSANIS BIO, INC.** [US/US]; 1111 Broadway, Suite 1300, Oakland, California 94607 (US).

(72) Inventors: **KLICKSTEIN, Lloyd Berl**; c/o Versanis Bio, Inc., 1111 Broadway, Suite 1300, Oakland, California 94606 (US). **MACHACEK, Matthias**; c/o Versanis Bio, Inc., 1111 Broadway, Suite 1300, Oakland, California 94607 (US).

(74) Agent: **COSTIGLIOLA, J. Nancy et al.**; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMBINATION THERAPIES




FIG. 1

(57) Abstract: The disclosure relates to the combined use of an ActRII pathway agent, e.g., an ActRII receptor antibody, and a GLP-1 agonist for the treatment of metabolic disorders, including obesity. As provided herein, the combination treatment reduces fat mass and maintains or increases lean mass.